We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

ORASURE TECHNOLOGIES

OraSure Technologies develops, manufactures and distributes oral fluid diagnostic and collection devices and other te... read more Featured Products: More products

Download Mobile App





ORAcollect RNA Saliva Collection Device for SARS CoV-2 Granted FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 04 Nov 2020
OraSure Technologies, Inc.’s (Bethlehem, PA, USA) subsidiary, DNA Genotek, has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for the use of the ORAcollect·RNA (OR/ORE-100) saliva collection device for the collection, stabilization and transport of saliva specimens suspected of containing SARS-CoV-2 RNA. More...


The ORAcollect·RNA collection device is an important component of molecular/PCR tests as laboratories are able to use it as the saliva sample collection method for their COVID-19 tests. This is the second FDA EUA received by DNA Genotek for its saliva collection devices. Similar to the EUA recently obtained by DNA Genotek for its OMNIgene·ORAL (OM/OME-505), the latest EUA allows for the unsupervised use of the device at-home or in a healthcare setting when used as a component of an authorized or cleared self-collection kit. This means it can be part of a kit that is authorized under its own EUA for use by an individual to collect saliva specimens at home.

“Accessible and accurate testing programs that include a non-invasive, saliva-based collection option will be essential throughout the duration of the COVID-19 pandemic,” said Kathleen Weber, Executive Vice President, Business Unit Leader, Molecular Solutions at DNA Genotek. “This second EUA gives our customers additional non-invasive options for SARS CoV-2 sample collection. Saliva sample collection is quick, painless, non-invasive and requires less human contact both minimizing the need for PPE and reducing exposure to potentially infected patients.”




Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.